RGEN
$119.27
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatogr...
Recent News
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.
2 Growth Stocks Set to Flourish and 1 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
3 Profitable Stocks We Keep Off Our Radar
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Reassessing Repligen (RGEN) Valuation After Sector Pullback And Profitability Concerns
Repligen (RGEN) is back in focus after a sector wide pullback, with the stock sliding 4.4% as investors reacted to healthcare job losses and fresh scrutiny of the company’s profitability trends. See our latest analysis for Repligen. That 4.4% one-day share price decline fits into a tougher stretch for Repligen, with a 1-month share price return of a 15.61% decline and a 1-year total shareholder return of a 22.94% decline. Sector-wide worries and questions about profitability trends have...
Evaluating Repligen (RGEN) After Sharp Share Price Declines and Conflicting Valuation Signals
If you are wondering whether Repligen at around US$119.99 is a bargain or still looks expensive, you are not alone. That is exactly what this article aims to unpack for you. Over the past week the stock has seen a 6.8% decline, extending to a 15.6% decline over 30 days and a 27.0% decline year to date, with a 22.9% decline over 1 year and a 27.8% decline over 3 years that compares with a 38.4% decline over 5 years. Recent coverage around Repligen has focused on its role in bioprocessing...